Clinical trials: Dupuytren Contracture
Dupuytren's Disease
Retreatment of Recurrent Dupuytren's Contractures
The objectives of this study are to assess the safety and efficacy of AA4500 in the retreatment of recurrent contractures in joints that were effectively treated with AA4500 in a previous Auxilium-sponsored Phase 3 study.
- Trial name
- NCT01498640
- Testing
- Collagenase clostridium histolyticum
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 52 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Dupuytren's Contracture
Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures
The primary objective of this study is to assess the safety of two concurrent injections of AA4500 into the same hand in subjects with multiple Dupuytren's contractures with palpable cords followed 24 to 72 hours later by a…
- Trial name
- NCT01674634
- Testing
- XIAFLEX / XIAPEX
- Where
- 25 sites in United States
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Dupuytren's Contracture
Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture
This is an observational study, meaning participants will not receive any investigational treatment as part of this study. Researchers will collect real-world data (RWD), based on usual care, to gain a more in-depth knowledge of…
- Trial name
- GRASP-DC (NCT05877066)
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Dupuytren's Contracture
A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture
A Phase 1, open-label, single-dose pharmacokinetic study in subjects with Dupuytren's contracture conducted at one site in the United States.
- Trial name
- NCT00528931
- Testing
- collagenase clostridium histolyticum
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Dupuytren's Disease
Longterm Observational Study in Subjects Treated With AA4500 in AUX-CC-854, 856, 857, 858 & 859
The purpose of study AUX-CC-860 is to assess the durability of response of the AA4500 treatment regimen. This study will also evaluate long-term safety and progression of disease in joints.
- Trial name
- NCT00954746
- Where
- 39 sites in United States, Australia and 4 more
- Volunteers
- 645 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Dupuytren Contracture, Dupuytren Disease of Finger
Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture
This trial is a multicenter, Phase 1/2, study to assess the safety, tolerability, efficacy, PK, and immunogenicity of CNT201 in adult participants with DC (Dupuytren's Contracture).
- Trial name
- NCT07640425
- Testing
- [Step1] CNT201 First-dose, [Step1] CNT201 Low-dose, [Step1] CNT201 Intermediate-dose
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- CONNEXT
Dupuytren's Contracture
Collagenase Option for Reduction of Dupuytren's Contracture in Japan
To investigate the efficacy and safety of AK160 in patients with Dupuytren's Contracture. To determine plasma concentration after the first injection of AK160 in patients with Dupuytren's Contracture.
- Trial name
- CORD-J (NCT01588353)
- Testing
- Collagenase Clostridium Histolyticum
- Where
- 20 sites in Japan
- Volunteers
- 104 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Dupuytren's Contracture
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture
This was a Phase 3, double-blind, randomized, placebo-controlled study conducted in the United States. Subjects with a diagnosis of Dupuytren's contracture in a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint…
- Trial name
- CORD-I (NCT00528606)
- Testing
- collagenase clostridium histolyticum
- Where
- 15 sites in United States
- Volunteers
- 308 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Dupuytren's Contracture
Administration of Two Injections for Multiple Dupuytren's Contractures
The objectives of this study are to assess the safety and efficacy of concurrent administration of two injections of AA4500 into the same hand of subjects with multiple Dupuytren's contractures caused by palpable cords.
- Trial name
- NCT01407068
- Testing
- AA4500 collagenase clostridium histolyticum
- Where
- 8 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Dupuytren's Contracture
Post Approval Commitment Study
An agreement has been made to conduct a post-approval commitment study that provides supplementary information relating to the use of Xiapex® as well as other non-pharmacological treatments for Dupuytren's contracture by health…
- Trial name
- NCT01444729
- Testing
- Xiapex, surgery
- Where
- 7 sites in Norway, Spain
- Volunteers
- 305 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Dupuytren's Contracture
Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)
This study will evaluate the impact of Xiapex treatment on the range of motion (ROM) of the affected fingers and the patient and physician reported treatment satisfaction and disease severity and their relation to ROM.
- Trial name
- POINT X (NCT01229436)
- Testing
- Xiapex
- Where
- 28 sites in Denmark, France and 6 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
Dupuytren's Disease
Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules
The objectives of this study are to assess the safety and effectiveness of AA4500 in treating palmar Dupuytren's disease nodules.
- Trial name
- NCT02193828
- Testing
- Collagenase clostridium histolyticum
- Where
- 11 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Dupuytren's Contracture
CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment
This observational study will prospectively collect data on treatment options, patient/investigator satisfaction, requirement for retreatment or additional treatment, and long-term outcomes of 3 treatment modalities(XIAFLEX…
- Trial name
- CORRECT (NCT01715467)
- Where
- 27 sites in United States
- Volunteers
- 162 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company